EUVIMEDEUVIMED entdecken
Crossref

Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection

Charles Béguelin iD, Bernard Surial, Eveline Hofmann, Lorin Begré, Aline Munting, Huldrych F Günthard, Marcel Stöckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch und 2 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.13766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Charles Béguelin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Tenofovir, Hepatitis B Surface Antigens, HIV Infections, Coinfection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: The European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT ID), Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis B surface antigen (HBsAg) loss is a rare event among persons with hepatitis B virus (HBV) monoinfection but seems to happen more frequently in people with HIV (PWH). We assessed the proportion of PWH/HBV coinfection who experienced HBsAg loss during long‐term tenofovir‐therapy and evaluated its association with quantitative HBsAg (qHBsAg) levels at tenofovir start.

Methods

All Swiss HIV Cohort Study participants with two or more positive HBsAg measurements more than 6 months apart, and at least 4 years of tenofovir‐containing antiretroviral therapy (ART), were considered. Our main outcomes were the loss of HBsAg during the first 2 years of tenofovir therapy and until the last available follow‐up. We explored the association between qHBsAg levels at tenofovir start and HBsAg loss using multivariable logistic regression adjusted for potential confounders.

Results

A total of 272 PWH and HBV coinfection were included. Median age was 41 years (IQR 36–46) and 81% (221) were men. At tenofovir start, 62% (169/272) received prior HBV active therapy, 49% (110/224) were hepatitis B e antigen (HBeAg)‐positive, 82% (222/272) had detectable HBV DNA (median 4.0 log10 IU/mL, IQR 2.1–7.5) and 19% (46/242) had low qHBsAg, defined as

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHepatitis B Surface AntigensHIV InfectionsCoinfectionAnti-HIV AgentsHepatitis BHepatitis B, ChronicHumansMaleAdultFemaleMiddle AgedCohort StudiesSwitzerland

Stichwörter der Autor:innen

HBsAg clearancecoinfectionhepatitis B virushuman immunodeficiency virusquantitative HBsAgtenofovir

Substanzen

TenofovirHepatitis B Surface AntigensAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Division of Infectious Diseases Ente Ospedaliero Cantonale, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.

ORCID-Profile: Charles Béguelin

Förderung

  • The European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT ID)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Béguelin, C., Surial, B., Hofmann, E., Begré, L., Munting, A., Günthard, H. F., Stöckle, M., Bernasconi, E., Schmid, P., Calmy, A., Suter-Riniker, F., Rauch, A., Wandeler, G., & Swiss HIV Cohort Study (SHCS) (2025). Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection. HIV Medicine. https://doi.org/10.1111/hiv.13766

Vancouver

Béguelin C, Surial B, Hofmann E, Begré L, Munting A, Günthard HF, et al. Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection. HIV Medicine. 2025. doi:10.1111/hiv.13766

BibTeX
@article{Bguelin2025,
  author = {Béguelin, Charles and Surial, Bernard and Hofmann, Eveline and Begré, Lorin and Munting, Aline and Günthard, Huldrych F and Stöckle, Marcel and Bernasconi, Enos and Schmid, Patrick and Calmy, Alexandra and Suter-Riniker, Franziska and Rauch, Andri and Wandeler, Gilles and Swiss HIV Cohort Study (SHCS), Swiss HIV Cohort Study (SHCS)},
  title = {Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV /hepatitis B virus coinfection},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.13766}
}
Kostenlos starten →